AK-Pred

Name: AK-Pred

AK-Pred Drug Class

AK-Pred is part of the drug classes:

  • Corticosteroids acting locally

  • Antiinflammatory Corticosteroids

  • Corticosteroids, weak group I

  • Corticosteroids, weak, other combinations

  • Corticosteroids/antiinfectives/mydriatics in combination

  • Glucocorticoids

If OVERDOSE is suspected

If you think there has been an overdose, call your poison control center or get medical care right away. Be ready to tell or show what was taken, how much, and when it happened.

How do I store and/or throw out AK-Pred?

  • Store at room temperature. Do not freeze.
  • Keep lid tightly closed.
  • Keep all drugs in a safe place. Keep all drugs out of the reach of children and pets.
  • Check with your pharmacist about how to throw out unused drugs.

For the Consumer

Applies to prednisolone ophthalmic: ophthalmic ointment, ophthalmic solution, ophthalmic suspension

Side effects include:

Elevated IOP, transient stinging or burning, blurred vision, ocular irritation, foreign body sensation.

Usual Adult Dose for Iritis

0.12% and 1% Ophthalmic Suspensions: Instill 1 to 2 drops into the conjunctival sac of the affected eye(s) 2 to 4 times a day; during the initial 24 to 48 hours, may increase dosing frequency if necessary

Comments:
-If signs/symptoms fail to improve after 2 days of treatment, the patient should be re-evaluated.
-Care should be taken as to not discontinue therapy prematurely.
-Anti-infective agents should me employed if a bacterial infection is present.
-Withdrawal of treatment should be carried out by gradually decreasing the frequency of applications when treating chronic conditions.

1% Ophthalmic Solution:
-Initial dose: Instill 1 to 2 drops into the conjunctival sac of the affected eye(s) up to every hour during the day and every 2 hours during the night as needed
-Maintenance dose: When a favorable response is observed, reduce dose to 1 drop every 4 hours; subsequent reduction to 1 drop 3 to 4 times a day may be adequate to control symptoms

Comments:
-Duration of therapy varies depending upon the type of lesion and may extend from a few days to several weeks, based on therapeutic response.
-Relapses, which are more common in chronic active lesions than in self-limited conditions, usually respond to retreatment.

Uses: For the treatment of steroid responsive mild to moderate noninfectious allergic and inflammatory disorders of the eye (e.g., allergic conjunctivits, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides); and for the treatment of corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies

Usual Adult Dose for Cyclitis

0.12% and 1% Ophthalmic Suspensions: Instill 1 to 2 drops into the conjunctival sac of the affected eye(s) 2 to 4 times a day; during the initial 24 to 48 hours, may increase dosing frequency if necessary

Comments:
-If signs/symptoms fail to improve after 2 days of treatment, the patient should be re-evaluated.
-Care should be taken as to not discontinue therapy prematurely.
-Anti-infective agents should me employed if a bacterial infection is present.
-Withdrawal of treatment should be carried out by gradually decreasing the frequency of applications when treating chronic conditions.

1% Ophthalmic Solution:
-Initial dose: Instill 1 to 2 drops into the conjunctival sac of the affected eye(s) up to every hour during the day and every 2 hours during the night as needed
-Maintenance dose: When a favorable response is observed, reduce dose to 1 drop every 4 hours; subsequent reduction to 1 drop 3 to 4 times a day may be adequate to control symptoms

Comments:
-Duration of therapy varies depending upon the type of lesion and may extend from a few days to several weeks, based on therapeutic response.
-Relapses, which are more common in chronic active lesions than in self-limited conditions, usually respond to retreatment.

Uses: For the treatment of steroid responsive mild to moderate noninfectious allergic and inflammatory disorders of the eye (e.g., allergic conjunctivits, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides); and for the treatment of corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies

Renal Dose Adjustments

Data not available.

Dialysis

Data not available.

Prednisolone ophthalmic Breastfeeding Warnings

It is unknown whether topically administered corticosteroids could result in sufficient systemic absorption to produce detectable levels in breast milk; however, systemically administered corticosteroids may appear in breast milk and could suppress growth, interfere with endogenous corticosteroid production, or cause untoward effects.

Use is not recommended. Excreted into human milk: Unknown Excreted into animal milk: Data not available Comments: -Due to limited absorption from the eye, this drug is not expected to cause any adverse effects in breastfed infants; however, due to the possibility an adverse effect may occur, a decision should be made to discontinue nursing or discontinue the drug. -Placing pressure over the tear duct by the corner of the eye for at least 1 minute and removing excess solution with an absorbent tissue substantially reduces the amount of drug that reaches breast milk after using eye drops.

Prednisolone Identification

Substance Name

Prednisolone

CAS Registry Number

50-24-8

Drug Class

Corticosteroids, Systemic

Corticosteroids, Ophthalmic

Glucocorticoids

Anti-Inflammatory Agents

(web3)